Everest Clinical Research, a comprehensive contract research organization (CRO), has announced its acquisition of August Research. Everest, backed by Arlington Capital Partners, a private equity firm based in Washington, D.C. specializing in regulated industries, now expands its European presence through this strategic move. The financial details of the transaction were not disclosed.
August Research, a European CRO, specializes in providing Clinical Trial Services (CTS) and Pharmacovigilance (PV) services to a diverse clientele in the pharmaceutical and biotechnology sectors. With a track record of over 120 projects spanning Phase I-IV clinical trials across various therapeutic areas including cardiovascular, infectious disease, oncology, and rare disease, August brings valuable expertise to the table. Dana Leff Niedzielska and Lukasz Niedzielski, the founders of August, along with other managing directors in their European offices, will remain integral executive leaders in the business after the acquisition.
August is renowned for its exceptional staff, adaptable approach, and extensive local European networks, along with deep knowledge of regional regulations. Everest's established strengths in delivering top-notch clinical trial data, analytical services, Interactive Response Technologies, pharmacovigilance, medical writing, and clinical operations services in North America complement August's robust European clinical operations, regulatory, and local pharmacovigilance capabilities. The merger of Everest and August Research's capabilities creates a global, comprehensive suite of clinical services for their diverse client base, opening up new avenues for growth for the combined entity.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!